Clinical Trial: Biomarkers in Patients With Advanced Rhabdomyosarcoma

Study Status: Completed
Recruit Status: Completed
Study Type: Observational

Official Title: Developmental Pathway Drug-Targets in Advanced Rhabdomyosarcomas

Brief Summary: This research trial studies tumor tissue to identify important proteins and biomarkers from patients with rhabdomyosarcoma that has spread to other places in the body and usually cannot be cured or controlled with treatment. Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors identify biomarkers related to cancer.

Detailed Summary:

PRIMARY OBJECTIVES:

I. To investigate whether the expression of a subset of proteins (by immunohistochemistry), known to be Involved in the paired box (Pax)3, Pax7, and Patched-1 neuromuscular development pathways, are dysregulated in advanced and relapsed alveolar and embryonal rhabdomyosarcomas.

OUTLINE:

Immunohistochemistry is performed for each candidate target (Pax3, Pax7, and Patched-1) in each disease (alveolar, embryonal, and anaplastic rhabdomyosarcoma) for tissue microarray analysis.

Sponsor: Children's Oncology Group

Current Primary Outcome: Prevalence of the candidate target (Pax3, Pax7, or Patched-1), and whether the candidate target is expressed in the tumor vs stroma [ Time Frame: 1 month ]

Original Primary Outcome: Prevalence of the candidate target (Pax3, Pax7, or Patched-1), and whether the candidate target is expressed in the tumor vs stroma

Current Secondary Outcome:

Original Secondary Outcome:

Information By: Children's Oncology Group

Dates:
Date Received: August 15, 2012
Date Started: August 2012
Date Completion:
Last Updated: May 17, 2016
Last Verified: May 2016